New COVID-19 initiatives/developments from healthcare companies include Bristol-Myers Squibb’s (NYSE:BMY) expansion of
its existing patient support program aimed at helping unemployed U.S.
patients who have lost their health insurance coverage due to the
pandemic. The company is offering its branded medicines at no charge,
including those prescribed via telehealth services. Shares up 2% premarket.
Karyopharm Therapeutics (NASDAQ:KPTI) plans to launch a global clinical trial evaluating low-dose Xpovio (selinexor) in severely ill hospitalized COVID-19 patients.
Teva Pharmaceutical Industries (NYSE:TEVA) Canadian unit and Huddol are offering free virtual personal assistance services
to families for 30 days via Huddol.com during the pandemic supported by
funding from Teva. Afterward, services will be available at a discount.
Shares up 3% premarket.
Infinity Pharmaceuticals (NASDAQ:INFI) expects enrollment to be delayed in its clinical trials as well as new site activations. Supply chain unaffected thus far.
https://seekingalpha.com/news/3558885-bristol-myers-squibb-to-provide-medicines-to-unemployed-and-uninsured
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.